You are in: eMedicine Specialties > Sports Medicine > Knee Medial Collateral Knee Ligament InjuryArticle Last Updated: May 30, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Thomas M DeBerardino, MD, Director, John A Feagin Jr West Point Sports Medicine Fellowship, Orthopedic Surgery Service, Clinical Instructor in Surgery, Keller Army Community Hospital at West Point Thomas M DeBerardino is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Medical Association, American Orthopaedic Association, and American Orthopaedic Society for Sports Medicine Coauthor(s): Jeffrey C Gundel, MD, Consulting Surgeon, Department of Orthopedic Surgery, North Country Sports Medicine Editors: Andrew L Sherman, MD, Associate Professor, Departments of Neurological Surgery, Orthopedics, and Rehabilitation, University of Miami Miller School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Russell D White, MD, Professor of Medicine, Department of Community and Family Medicine, University of Missouri-Kansas City School of Medicine, Truman Medical Center Lakewood; Jon Whitehurst, MD, Consulting Staff, Rockford Orthopedic Associates; Wylie D Lowery, Jr, MD, Department of Orthopedic Surgery, Associate Professor, George Washington University Author and Editor Disclosure Synonyms and related keywords: MCL injury, tibial collateral knee ligament injury, TCL injury, torn ligament, knee injury INTRODUCTIONBackgroundMedial collateral ligament (MCL) injuries of the knee are very common sports-related injuries. The MCL is the most commonly injured knee ligament. Injuries to the MCL occur in almost all sports and in all age groups. FrequencyUnited StatesThe incidence of MCL injuries is impossible to determine because of the wide spectrum of injury severity. Many MCL injuries are minor and may never be evaluated by a physician. Functional AnatomyThe medial aspect of the knee has been divided into 3 distinct layers based on cadaver dissection. The first layer is the deep fascia, which consists of the sartorius fascia anteriorly and a thin fascial layer posteriorly. The thin posterior fascia covers the popliteal fossa and the heads of the gastrocnemius muscle. The second layer includes the superficial MCL, also known as the tibial collateral ligament. This ligament attaches proximally to the medial femoral epicondyle and to the tibia distally, approximately 4-5 cm distal to the joint line. The parapatellar retinaculum and patellofemoral ligament are within this layer. The third layer is the knee joint capsule, which attaches proximally and distally at the articular margins. The capsule is divided into thirds from anterior to posterior. The anterior third of the capsule is the thinnest portion. It is attached to the anterior horn of the medial meniscus and is reinforced by the medial retinaculum. The middle third of the capsule consists of the deep medial collateral ligament. It is firmly attached to the mid body of the medial meniscus. Proximal to the meniscal attachment, it is termed the meniscofemoral ligament. Distal to its meniscal attachment, it is termed the meniscotibial ligament. The posterior third of the capsule includes the posterior oblique ligament (POL) and the oblique popliteal ligament. The POL has 3 arms, the superficial, tibial, and capsular. Sport Specific BiomechanicsThe superficial MCL has been shown through serial cutting studies to provide the primary restraint to valgus loads at all degrees of flexion. It is also an important restraint to anterior tibial translation when the anterior cruciate ligament is injured. The superficial MCL acts as a primary restraint to external rotation of the tibia. Stability of the medial side of the knee is provided by dynamic and static restraints. The static restraints are the superficial MCL and the joint capsule, including the deep MCL and the POL. The semimembranosus muscle, the pes anserine muscles, and the vastus medialis muscle provide dynamic stability. The muscles of the pes include the sartorius, gracilis, and semitendinosus. These muscles flex and internally rotate the tibia. The semimembranosus has 4 attachments: direct, tibial, inferior, and capsular. CLINICALHistoryA thorough history should be obtained prior to performing the physical examination. The following questions should be answered:
PhysicalA complete physical examination of the knee should be performed after a thorough history is obtained. Attention should be directed toward localizing the MCL injury and identifying any associated injuries.
CausesContact, noncontact, and overuse mechanisms are involved in causing MCL injuries.
DIFFERENTIALSFemur Injuries and Fractures
|
| Drug Name | Ibuprofen (Ibuprin, Motrin) |
|---|---|
| Description | DOC for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. |
| Adult Dose | 200-400 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d |
| Pediatric Dose | <6 years: Not established 6 months to 12 years: 4-10 mg/kg/dose PO tid/qid >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Naproxen (Anaprox, Naprosyn, Naprelan, Aleve) |
|---|---|
| Description | For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which results in a decrease of prostaglandin synthesis. |
| Adult Dose | 500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
| Drug Name | Ketoprofen (Orudis, Oruvail, Actron) |
|---|---|
| Description | For relief of mild to moderate pain and inflammation. Small dosages are initially indicated in small and elderly patients and in those with renal or liver disease. Doses >75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patient for response. |
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 300 mg/d |
| Pediatric Dose | <3 months: Not established 3 months to 12 years: 0.1-1 mg/kg PO q6-8h >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Sulindac (Clinoril) |
|---|---|
| Description | Decreases activity of cyclooxygenase and in turn inhibits prostaglandin synthesis. Results in a decreased formation of inflammatory mediators. |
| Adult Dose | 150-200 mg PO bid or 300-400 qd; not to exceed 400 mg/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; aspirin-, iodide-, or other NSAID-induced hypersensitivity; GI bleeding; renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in preexisting renal disease or compromised renal perfusion; low white blood cell counts occur rarely and usually return to reference range in ongoing therapy; discontinuation of therapy may be necessary if persistent leukopenia, granulocytopenia, or thrombocytopenia occurs; caution in anticoagulation defects or in persons who are receiving anticoagulant therapy |
Pain control is essential to quality patient care. Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who have sustained trauma or have sustained injuries.
| Drug Name | Propoxyphene and acetaminophen (Darvocet N-100) |
|---|---|
| Description | Drug combination indicated for mild to moderate pain. |
| Adult Dose | 1-2 tab PO q4h prn; not to exceed 600 mg/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | May increase serum concentrations of MAOIs, tricyclic antidepressants, carbamazepine, phenobarbital, and warfarin |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in patients dependent on opiates, substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Acetaminophen (Tylenol, Feverall, Aspirin-Free Anacin, Tempra) |
|---|---|
| Description | DOC for pain in patients with documented hypersensitivity to aspirin or NSAIDs, with upper GI disease, or who are taking PO anticoagulants. |
| Adult Dose | 325-650 mg PO q4-6h or 1000 mg tid/qid; not to exceed 4 g/d |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d >12 years: 325-650 mg PO q4h; not to exceed 5 doses in 24 h |
| Contraindications | Documented hypersensitivity; known G-6-PD deficiency |
| Interactions | Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Hepatotoxicity possible in people with long-term alcoholism following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; APAP is contained in many OTC products and combined use with these products may result in cumulative APAP doses exceeding recommended maximum dose |
| Drug Name | Acetaminophen and codeine (Tylenol and codeine) |
|---|---|
| Description | Indicated for the treatment of mild to moderate pain. |
| Adult Dose | 30-60 mg/dose based on codeine content PO q4-6h or 1-2 tab q4h; not to exceed 4 g/d of acetaminophen |
| Pediatric Dose | 0.5-1 mg/kg/dose based on codeine PO q4-6h; 10-15 mg/kg/dose based on acetaminophen content; not to exceed 2.6 g/d of acetaminophen |
| Contraindications | Documented hypersensitivity |
| Interactions | Toxicity of codeine increases with CNS depressants, tricyclic antidepressants, MAOIs, neuromuscular blockers, CNS depressants, phenothiazines, and narcotic analgesics Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity of acetaminophen |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in patients dependent on opiates because this substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction Hepatotoxicity with acetaminophen possible in people with long-term alcoholism following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; acetaminophen is contained in many OTC products, and combined use with these products may result in cumulative acetaminophen doses that exceed recommended maximum dose |
| Drug Name | Hydrocodone and acetaminophen (Vicodin, Lortab, Norcet, Margesic) |
|---|---|
| Description | Drug combination indicated for moderate to severe pain. |
| Adult Dose | 1-2 tab or cap PO q4-6h prn |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d acetaminophen >12 years: 750 mg acetaminophen PO q4h; not to exceed 10 mg hydrocodone bitartrate per dose or 5 doses/24 h |
| Contraindications | Documented hypersensitivity; high altitude cerebral edema (HACE); elevated intracranial pressure (ICP) |
| Interactions | Coadministration with phenothiazines may decrease analgesic effects; toxicity increases with CNS depressants or tricyclic antidepressants |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Tabs contain metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates because this substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Hydrocodone and ibuprofen (Vicoprofen) |
|---|---|
| Description | Drug combination indicated for short-term (<10 d) relief of moderate to severe acute pain. |
| Adult Dose | 1-2 tab PO q4-6h prn pain; not to exceed 5 tab/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; third trimester of pregnancy |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in impaired renal function, peptic ulcer disease, impaired thyroid function, asthma, hypertension, edema, heart failure, increased intracranial pressure, and erosive gastritis; duration of action may increase in elderly patients |
| Drug Name | Oxycodone and acetaminophen (Percocet, Roxilox, Roxicet, Tylox) |
|---|---|
| Description | Drug combination indicated for the relief of moderate to severe pain. |
| Adult Dose | 1-2 tab or cap PO q4-6h prn |
| Pediatric Dose | 0.05-0.15 mg/kg/dose oxycodone PO q4-6h prn; not to exceed 5 mg/dose of oxycodone |
| Contraindications | Documented hypersensitivity |
| Interactions | Phenothiazines may decrease analgesic effects of this medication; toxicity increases with coadministration of either CNS depressants or tricyclic antidepressants |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Duration of action may increase in elderly patients; be aware of total daily dose of acetaminophen patient is receiving; do not exceed 4,000 mg/24h of acetaminophen; higher doses may cause liver toxicity |
Return to play is allowed when sport-specific agility testing is completed comfortably. Usually this requires 90% return of strength compared to the contralateral knee.
Grade 1 and 2 sprains often allow return to play within 1-2 weeks. Grade 3 injuries usually require at least 6 weeks for return to play, although some authors have reported 3-4 weeks.
Late instability can occur, requiring operative intervention.
Prophylactic bracing is controversial, although many athletes wear braces. Some studies recommend bracing after showing a decrease in injury rate. Older studies did not show a decrease in injuries, and some actually demonstrated a slightly increased rate of injuries.
Patients with grade 1 and 2 injuries consistently recover well, and athletes return to play early. Patients with isolated grade 3 injuries also consistently return to full preinjury level, but recovery takes longer.
For excellent patient education resources, visit eMedicine's Breaks, Fractures, and Dislocations Center and Sports Injury Center. Also, see eMedicine's patient education article Knee Injury.
Medial Collateral Knee Ligament Injury excerpt
Article Last Updated: May 30, 2006